Variations within hepatitis C virus E2 protein and response to interferon treatment

Area of Science:

• Virology
• Hepatology
• Immunology

Background:

• Hepatitis C virus (HCV) infection remains a global health concern.
• Interferon-alfa therapy has been a cornerstone treatment for HCV, but response rates vary significantly among patients.
• Identifying predictors of treatment response is crucial for optimizing patient management.

Purpose of the Study:

• To investigate the role of the hepatitis C virus (HCV) E2 PePHD sequence in determining interferon treatment response.
• To compare the significance of E2 PePHD variations with NS5A ISDR variations in predicting treatment outcomes.

Main Methods:

• Analysis of E2 PePHD sequences (amino acids 659-670) in HCV-infected patients undergoing interferon-alfa treatment.
• Correlation of PePHD sequence types (wild-type vs. variations) with treatment response categories (non-responder, partial responder, complete responder).
• Analysis of NS5A ISDR sequences (amino acids 2209-2248) in HCV-1b infected patients.

Main Results:

• All non- or partial responders (6/6) possessed the wild-type E2 PePHD sequence (RSELSPLLL-TT).
• Over half of complete responders (5/9) exhibited sequence variations in the E2 PePHD region.
• No significant correlation was observed between NS5A ISDR sequence variation and interferon response in HCV-1b patients.

Conclusions:

• The E2 PePHD sequence appears to be a more significant determinant of interferon treatment response than the NS5A ISDR sequence.
• Wild-type E2 PePHD sequences are associated with poor or partial response to interferon therapy.
• Sequence variations in the HCV E2 PePHD domain may predict successful outcomes with interferon treatment.